Papatheodorou G, Kutcher S
Division of Adolescent Psychiatry, Sunnybrook Health Science Centre, University of Toronto Clinic, Ontario, Canada.
J Psychiatry Neurosci. 1995 May;20(3):226-32.
Seven adolescents or young adults (aged 16 to 22 years) who met DSM-III-R criteria for bipolar disorder were treated for persistent depressive symptoms (greater than three weeks) with adjunctive light therapy (10,000 lux given twice per day). Patients were evaluated using the Beck Depression Inventory (BDI) and Symptoms Check List (SCL-58). Three patients showed a marked response of greater than 70% decrease of their baseline score. Two patients had a moderate decrease (40% to 74%) and two patients obtained mild to no response. There were no reported side-effects. Paired t-tests done on pre- and post-BDI scores (pre mean = 21.2 sd +/- 10.0; post mean = 11.1, sd +/- 8.8; paired t = 4.31; p > 0.0051) and pre- and post-SCL-58 scores above baseline of 58 (pre mean = 57.4, sd +/- 24.4; post mean = 28.7, sd +/- 18.6; paired t = 5.50; p > 0.0015) showed significant improvement. These preliminary results indicate that some bipolar adolescents with breakthrough depressive symptoms could benefit from light therapy as an adjunct to their continued thymoleptic treatment.
七名符合DSM-III-R双相情感障碍标准的青少年或青年（年龄在16至22岁之间）因持续性抑郁症状（超过三周）接受了辅助光疗（每天两次，每次10,000勒克斯）治疗。使用贝克抑郁量表（BDI）和症状清单（SCL-58）对患者进行评估。三名患者表现出显著反应，基线分数下降超过70%。两名患者有中度下降（40%至74%），两名患者反应轻微或无反应。未报告有副作用。对BDI评分前后（前均值 = 21.2，标准差±10.0；后均值 = 11.1，标准差±8.8；配对t = 4.31；p>0.0051）以及SCL-58评分前后（高于基线58分，前均值 = 57.4，标准差±24.4；后均值 = 28.7，标准差±18.6；配对t = 5.50；p>0.0015）进行的配对t检验显示有显著改善。这些初步结果表明，一些有突破性抑郁症状的双相情感障碍青少年可能从光疗作为其持续心境稳定剂治疗的辅助手段中获益。
